NewsBenzinga프로세사 파마슈티컬스, 만성 자발성 두드러기 치료제 VT-7208의 2상 임상시험을 위한 FDA 신약 임상시험계획 승인 발표 프로세사 파마슈티컬스, 만성 자발성 두드러기 치료제 VT-7208의 2상 임상시험을 위한 FDA 신약 임상시험계획 승인 발표 Benzinga 2026.10.29 12:11 (GMT+0) Open on Benzinga Other news A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory